Resourcer and Trainee Recruiter roles at CK!

Interested in a career in recruitment and looking to work with a company who do something a bit different?

The CK Group are a specialist Scientific, Clinical, IT and Engineering recruitment consultancy dealing with the chemical, pharmaceutical, biotechnology, environmental, waste and food industries within the UK and Europe, providing both contract and permanent employment.

We are currently recruiting for Resourcers and Trainee Recruiters to increase our growing recruitment team. These individuals need to be outgoing with lots of personality who are hungry for success and will enjoy the satisfaction of providing a quality, professional service to both clients and candidates.

If you are interested in these roles, please find more information here.

Posted in Job News, Mobile News, NewsTagged in , , , , , , ,

CK Team Building Day – Coghlans Cookery School

The CK Team donned their aprons earlier this month for the annual team building day.

A great day was had by all at Coghlans Cookery School in Chesterfield – where we cooked a gourmet 3 course lunch and canapés!

Lunch menu:

–          Spinach and ricotta ravioli with pesto

–          Chicken stuffed with wild mushrooms and sun dried tomatoes wrapped in parma ham

–          Focaccia bread

–          Tiramisu

–          Panna cotta


–          Chicken with peppers, garlic and olive oil

–          Confit of duck with mango chutney

–          Melon with mango salsa

Team spirit was high with each team dressing in their chosen team costumes – we had everything from chefs hats to bandanas and moustaches.

4744787015_5ccf4dc620    4744799773_01071d25e9    4745429644_efd6d6b33a    4745468784_c50a5cd471    4745434644_03681b5017    4745426938_c9864d1834

Posted in General, NewsTagged in , , , , , , , ,

Teva Buys Ratiopharm in Generic Drugs Deal

Teva and Ratiopharm DealAs reported by the  BBC News the Israeli drugs giant, Teva has bought Germany’s second largest generics drug firm Ratiopharm for £3.2bn. Teva beat rival bids from U.S. pharmaceutical powerhouse Pfizer and Iceland’s Actavis.

Teva is already the world’s largest generic drug maker, and as a result of this deal is now number one in Europe, beating Novartis’ generics unit. The deal is also set to increase their presence in Spain, Italy and France.

Teva’s Chief Executive Shlomo Yanai stated, “This is an important acquisition for Teva, This transaction is perfectly aligned with our long-term strategy in which Europe is an important pillar and growth-driver.”

Generics are based around drug patents that have expired, allowing companies to both manufacture and sell them and is therefore seen as a high growth market.

CKS01twittercksciencelinkedinfacebookckclinical youtube

Posted in General, NewsTagged in , , , , , , , , , , , , , , , , , ,

CK Exhibit at the DIA 22nd Annual EuroMeeting

CK Clinical at the DIAThis year, the DIA (Drug Information Association) chose Monaco and its state-of-the-art Grimaldi Forum to hold it’s 22nd Annual EuroMeeting, and CK Clinical, sister company of CK Science, had the pleasure of attending.

The DIA Annual EuroMeeting is the largest event of its kind in Europe.  From the 8-10th March 2010, 3,000 professionals from biopharmaceutical industry, contract service organisations, academic research centres, regulatory agencies, health ministries, patient organisations and trade associations, descended on Monaco.

CK Clinical’s first visit to the DIA Conference was a resounding success. Pharmaceutical jobs were brought in across all sectors, and the conference definitely acted as a brilliant springboard kick off our campaign to enter the European market.

We also ran a prize draw to win an Apple iPod Touch, the winner being a Departmental Manager from Novo Nordisk in Denmark. Thank you to everybody that entered.

056The Grimaldi Forum was an impressive waterfront venue, filled with daylight and a stunning glass entrance. A perfect venue to network with clients. Monaco was incredible with Ferrari’s, Mercedes Benz and Bentleys everywhere you looked. The hotel even had its own helipad!

We are very much looking forward to attending and exhibiting at next year’s DIA Conference in Geneva.


CKS01linkedintwittercksciencefacebookckclinical youtube

Posted in General, NewsTagged in , , , , , , , , , , , ,

AstraZeneca to Cut 1,200 UK Pharmaceutical Jobs

Science Job CutsAs reported on the Times Online, the Pharmaceutical Industry giant, AstraZeneca plans to cut 1,200 UK Pharmaceutical jobs. The job cuts are a result of the company’s suspension of their research into various disease areas.

The company plans to close its research and development facility based in Leicestershire, along with another small plant in Cambridge.  Pharmaceutical development work at the Avlon facility near Bristol will also cease. Some of the workers will move to the company’s Alderly Park in Cheshire which is AstraZeneca’s largest research and development plant.

This will come as disappointing news to the Government, who created the Office of Life Sciences last year in a bid to increased the number of science and pharmaceutical jobs. The head of the Office of Life Sciences, Lord Drayson, said “I’m obviously disappointed that AstraZeneca is closing Charnwood, but the announcement that Alderley Park will become one of AstraZeneca’s top three global R&D sites shows that the UK remains an attractive location for investment in pharmaceuticals.”

Earlier in the year, AstraZeneca announced that they planned to cut 8,000 jobs around the world by 2014, including 3,500 in research and development, as part of a large-scale refocusing of the business.

Have you been effected by redundancy? Search for pharmaceutical jobs in your area now.

CKSciencelinkedintwittercksciencefacebook youtube

Posted in General, NewsTagged in , , , , , , , , , , , , , , , , , , , , ,

GSK to Cut 380 Pharmaceutical Jobs in Harlow, UK

redundancy[1]The global pharmaceutical company, GlaxoSmithKline (GSK) have announced that they will be cutting 380 pharmaceutical jobs at their site in Harlow, Essex. The site currently employs 1,150 staff. The cuts come as projects for pain relief, anxiety and depression drugs come to an end. Despite reporting an annual rise in profits of 12% earlier this year, the pharma company are still stressing the need to make cost savings.

GSK’s CEO, Andrew Witty stated that “Glaxo would discontinue research in some areas including depression and pain, and would focus more on degenerative and inflammatory diseases such as Alzheimer’s disease and Parkinson’s disease.”


Glaxo has its headquarters in Brentford, Middlesex, and research bases at Stevenage and Ware in Hertfordshire and Harlow in Essex.

Worried about redundancy? Search for Pharmaceutical Jobs in the UK now.

Posted in General, NewsTagged in , , , , , , , , , , , , , , ,